Borealis Biosciences

Ownership

Private

Employees

~25

Therapeutic Areas

Nephrology

Stage

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

RNA therapeuticsxRNA

Borealis Biosciences General Information

Borealis Biosciences is a discovery-stage biotechnology company focused on developing RNA medicines for kidney diseases. The company emerged from stealth in August 2024 with $150 million in combined Series A financing and strategic research collaboration funding.

Contact Information

Website

https://www.borealisbio.com/

Primary Industry

Biotech

Corporate Office

Vancouver, British Columbia
Canada

Drug Pipeline

No pipeline data available

For full access to Borealis Biosciences's pipeline data

Book a demo

Key Partnerships

Novartis (strategic research collaboration)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Borealis Biosciences Funding

Deal Type	Date	Amount	Status	Stage
Investment	Dec 19, 2024	$30.0M	Completed	Preclinical

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Borealis Biosciences's complete valuation and funding history, request access »